Associated Genetic Biomarkers
FLCN Loss is present in 0.20% of AACR GENIE cases, with breast invasive ductal carcinoma, colon adenocarcinoma, high grade ovarian serous adenocarcinoma, small cell lung carcinoma, and bladder urothelial carcinoma having the greatest prevalence .
FLCN Loss serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains FLCN Loss as an inclusion criterion, 1 is phase 2 (1 open).
Trials with FLCN Loss in the inclusion eligibility criteria most commonly target B-cell non-hodgkin lymphoma, malignant solid tumor, and multiple myeloma .
Temsirolimus is the most frequent therapy in trials with FLCN Loss as an inclusion criteria .
Significance of FLCN Loss in Diseases
B-Cell Non-Hodgkin Lymphoma +
FLCN is altered in 1.48% of B-cell non-hodgkin lymphoma patients with FLCN Loss present in 0.62% of all B-cell non-hodgkin lymphoma patients .
FLCN Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLCN Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) .
Malignant Solid Tumor +
FLCN is altered in 1.61% of malignant solid tumor patients with FLCN Loss present in 0.16% of all malignant solid tumor patients .
FLCN Loss is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FLCN Loss and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
Multiple Myeloma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.